title: [Oncologic outcome of 11.6 lipofilling procedures for reconstructive breast surgery].
abstract: OBJECTIVE
  Autologous fat graft injection has been systematically used by our team since 2001 in order to enhance the esthetic outcome of breast reconstruction. However, this technique remains controversial, notably in France. This study evaluated oncologic outcomes at 3 years among 110 patients operated on and monitored by two surgeons.
  
  
  METHODS
  116fat graft injections in 110 patients who required reconstructive breast surgery between January 2001 and December 2011 were included in the analysis of oncologic outcomes. The AJCC (American Joint Committee on Staging) stages were: stage 0 (18 %), stage I (44 %), stage II (26.7 %), and stage III (11.3 %). Mean follow-up was 6.3 years (9 months to 17 years) after initial breast cancer surgery, and 3 years (6 months to 9.5 years) after the last lipofilling procedure.
  
  
  RESULTS
  The majority of patients (91.8 %) are alive and recurrence-free. Remote metastases occurred in 8.2 % of patients: one patient had a local and systemic recurrence, one patient had a local, regional and systemic recurrence.
  
  
  CONCLUSIONS
  Although confirmation is needed from multicenter randomized trials with longer follow-up, a larger group of patients and a control group matched for the cancer status of the lipofilling group, our results support the view that lipofilling has little or no effect on the risk of locoregional recurrence of breast cancer.
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Missana
authors.forename: Michel A
authors.initials: MA
authors.lastname: Germain
mesh_terms: D000273:Adipose Tissue; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D000067548:Dermal Fillers / Q000008:administration & dosage*; D018572:Disease-Free Survival; D004967:Estrogens; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007279:Injections, Subcutaneous; D016462:Mammaplasty / Q000009:adverse effects / Q000379:methods* / Q000706:statistics & numerical data; D008408:Mastectomy; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000453:epidemiology / Q000473:pathology / Q000601:surgery / Q000628:therapy; D011374:Progesterone; D012189:Retrospective Studies; D013524:Surgical Flaps; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D000067548:Dermal Fillers; D004967:Estrogens; D011374:Progesterone